Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413218 · ClinicalTrials.gov registry record · Phase 3
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
A Phase 3 study of Candidemia and Mycoses, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT00413218 is a Phase 3 study of Candidemia and Mycoses that has completed, run by Astellas Pharma. The registered enrollment target is 450 participants, above the 358-participant average among 8 other Candidemia trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT00413218, a Phase 3 study of Candidemia and Mycoses, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
Conditions Studied
Interventions
- DRUG Caspofungin
- DRUG Isavuconazole
- DRUG Voriconazole
Study Locations (20)
California
- Somero Research Corporation - Palm Desert
- University of California Davis Health System - Sacramento
- University of California at San Francisco - San Francisco
Illinois
- Loyola University Hospital - Maywood
- Springfield Clinic LLP - Springfield
Other
- Hospital Britanico de Buenos Aires - Capital Federal
- Hospital General de Agudos Dr. Carlos G. Durand - Capital Federal
Alabama
- University of Alabama at Birmingham - Birmingham
Idaho
- Idaho Falls Infectious Diseases PLLC - Idaho Falls
Indiana
- Infectious Disease of Indiana - Indianapolis
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maryland
- University of Maryland School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2007-03-08 |
| Est. Completion | 2015-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413218
The ClinicalTrials.gov registry entry for NCT00413218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 358-participant average among 8 other Candidemia trials with a reported enrollment target (26% higher). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Candidemia appearing as the primary indexed condition, and to 3 interventions - of which Caspofungin is the first listed.
NCT00413218 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Illinois, Other.
Frequently Asked Questions
What is clinical trial NCT00413218 about?
NCT00413218 is a clinical study titled "Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections". The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
What is the current status of trial NCT00413218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2007-03-08. Estimated completion is 2015-03-03.
What conditions does trial NCT00413218 study?
This clinical trial studies the following conditions: Candidemia, Mycoses, Candidiasis, Invasive.
What interventions are being tested in trial NCT00413218?
The interventions under investigation include: Caspofungin (DRUG), Isavuconazole (DRUG), Voriconazole (DRUG).
Who is sponsoring clinical trial NCT00413218?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00413218 being conducted?
This trial has 20 study locations across Alabama, California, Idaho, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
COMPLETED · Phase 3
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.